Screener / SEC EDGAR /CIK 0000886163 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq, OTC Health care · Pharmaceuticals

Ligand Pharmaceuticals Inc LGND

We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. 10-K, Item 1

Headquarters
San Diego, CA
CEO
Todd C. Davis
Next results
around Feb 25, 2027
Compare with peers Embed

LGND among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 60.4%, above 92% of 154 peers (their median 10.4%) REVENUE GROWTH 60.4% · above 92% Operating margin: 10.2%, above 51% of 138 peers (their median 9.8%) OPERATING MARGIN 10.2% · above 51% Net margin: 20.3%, above 86% of 153 peers (their median 6.7%) NET MARGIN 20.3% · above 86% FCF margin: 35.7%, above 97% of 144 peers (their median 9.9%) FCF MARGIN 35.7% · above 97% Return on capital: 1.5%, above 4% of 89 peers (their median 9.2%) RETURN ON CAPITAL 1.5% · above 4%
LGND Peer median Below the median

What changed

45 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 27, 2026 against Feb 28, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Cash from operations lower than net income
    Cash from operations $49.4M vs net income $124.5M (FY ending Dec 31, 2025)
  • Receivables +55.3% ($38.4M to $59.6M) vs revenue +60.4% ($167.1M to $268.1M), -5.1 pts apart
9 more checks with nothing to note
  • Inventory -35.3% ($14.1M to $9.1M) vs revenue +60.4% ($167.1M to $268.1M), -95.7 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No longer listed: Valuation of Agenus partnered programs in Agenus acquisition. Same as last year: Impairment assessment of finite-lived intangibles; Financial royalty assets - recognition of income
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

45 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.

All 45 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    The royalty market may not grow at the same rate as it has in the past, or at all, and we may not be able to acquire sufficient royalties to sustain the growth of our business. We have been able to grow our business over time by primarily acquiring royalties. However, we may not be able to identify and acquire a sufficient number of…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    The manufacture and distribution of a biopharmaceutical product may be interrupted by regulatory agencies or supplier deficiencies. The manufacture of products generating our royalties is typically complex and is highly regulated. In particular, biopharmaceutical products are manufactured in specialized facilities that require the…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    In addition, our collaboration partners may develop products, either alone or with others, that compete with the types of products they are developing with us (or that we are developing on our own). This would result in increased competition for our
  4. Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
    We may undertake strategic acquisitions of operating biopharmaceutical companies or acquire securities of biopharmaceutical companies. Our failure to realize the expected benefits of such acquisitions could adversely affect our business, financial condition or results of operations.

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$196.2M$131.3M$167.1M$268.1M
Net income−$33.4M$52.2M−$4.0M$124.5M
Operating cash flow$137.8M$49.6M$97.0M$49.4M
Free cash flow$119.9M$46.1M$95.2M$48.9M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$268.1M ▲ 60.4% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

12 filings in the last 30 days · SEC EDGAR

All filings
7 more

About the company

Ligand Pharmaceuticals Inc, San Diego, CA · from the 10-K filed Feb 27, 2026

We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure. Capital deployment and technology licensing are the primary drivers of our long-term growth.

Headquarters
San Diego, CA
Country
United States
Reports in
USD
Listed on
Nasdaq, OTC
Fiscal year ends
December 31
Last results
Oct 29, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Feb 27, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LGND/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.